loading page

Undifferentiated embryonal sarcoma of the liver: First case reported in Central America
  • Amilcar Antonio Alfaro García,
  • Ludwing Bacon Fonseca,
  • Maria del Rosario Romero Alvarez
Amilcar Antonio Alfaro García
Manolo Morales Peralta Hospital

Corresponding Author:aalfarog201@gmail.com

Author Profile
Ludwing Bacon Fonseca
Manolo Morales Peralta Hospital
Author Profile
Maria del Rosario Romero Alvarez
Hospital Vivian Pellas
Author Profile

Abstract

Background: Undifferentiated embryonal sarcoma of the liver (UESL) is an aggressive mesenchymal tumor that usually occurs in children. When it occurs in adults, it poses a diagnostic challenge for the medical team. The clinical manifestations are not specific, imaging studies show a hepatic mass with a mixed component (solid and cystic). To date, surgical resection with neoadjuvant therapy has yielded satisfactory results in terms of survival. Case: We present the case of a 19-year-old patient, which, to our knowledge is the only case reported in Central America, which was surgically resected and received adjuvant chemotherapy. The patient has been followed for 34 months, and she remains free of disease. Conclusion: The presented case highlights the need to raise awareness about UESL in the Central American region and promote a comprehensive diagnostic and therapeutic approach to improve disease-free survival in these patients.
20 Apr 2024Submitted to Cancer Reports
14 Jul 2024Review(s) Completed, Editorial Evaluation Pending
26 Jul 2024Editorial Decision: Revise Major
22 Aug 20241st Revision Received
23 Aug 2024Submission Checks Completed
23 Aug 2024Assigned to Editor
23 Aug 2024Review(s) Completed, Editorial Evaluation Pending
23 Aug 2024Reviewer(s) Assigned
12 Sep 2024Editorial Decision: Revise Minor
17 Sep 20242nd Revision Received
25 Sep 2024Submission Checks Completed
25 Sep 2024Assigned to Editor
25 Sep 2024Review(s) Completed, Editorial Evaluation Pending
27 Sep 2024Reviewer(s) Assigned
14 Oct 2024Editorial Decision: Revise Minor
16 Oct 20243rd Revision Received
22 Oct 2024Submission Checks Completed
22 Oct 2024Assigned to Editor
22 Oct 2024Review(s) Completed, Editorial Evaluation Pending
23 Oct 2024Reviewer(s) Assigned
12 Nov 2024Editorial Decision: Accept